TASK is a generalist clinical research institute, able to perform many services and complex clinical trials in a wide variety of therapeutic areas.
Our collective tacit knowledge gained over the 16 years of performing these complex trials provides us with a distinct advantage to tackle challenging projects.
Further, our world class clinical trial sites are set up in various different communities in the Western Cape of South Africa, an area renown for first world infrastructure in a third world setting. This offers a unique trial experience, leveraging first world infrastructure such as access to an excellent basic standard of medical care, high speed internet, reliable air travel and efficient logistics, against an informal community setting where clinical research is respected and appreciated.
Our close link with these communities via various independent Community Advisory Boards (CABs) further sets us up with an advantage to recruit participants efficiently, having assisted lay a foundation of clinical and research literacy amongst those communities from which we recruit.
TASK is also a world renown research specialist in infectious diseases, most notably in tuberculosis, COVID-19 treatment and vaccines, with various awards and accolades bestowed on our Principle Investigators over the years and several high profile publications sharing our trial data.
Some of these can be found here: https://pubmed.ncbi.nlm.nih.gov/?term=Diacon+AH&sort=date
Mostly notably, several publications and numerous citations can be found in the New England Journal of Medicine. Similarly, TASK’s founder and current CEO, Professor Andreas Diacon has been noted by the Bill and Melinda Gate’s Foundation as a ‘hero in the field’ for his contribution to TB drug development.
Of note, TASK is world renowned for its Early Bacterial Activity (EBA) studies, where efficacy of a novel antibiotic agent can be determined over a 14 -day period, this saving a significant investment of time and resources in further progressing non-potential showing novelties through further clinical evaluation.
Other areas of that TASK has experience in include:
- Anti-Microbial Resistance (AMR) research
- Biosimilar development
- Cardio metabolic disease
- Immunology & Inflammation
- Pain Management
- Neglected Tropical Diseases
- Evaluation of medical devices and diagnostics
Clinical evaluation is required in order for a new medical treatment, medical device or vaccine to be made available for public use or be “market ready”. Robust testing, mandated by governmental regulatory authorities and closely monitored by safety and ethics committees, takes place. This is what we refer to as clinical trials.
TASK performs clinical trials to evaluate the effectiveness and safety of medical therapies by monitoring their effects on groups of volunteers. This includes medicines for treatment of diseases and illness, vaccines and medical devices.
This is usually performed on behalf of pharmaceutical companies, medical device manufacturers and government funded consortiums.
Testing occurs in four phases within the ‘in-human’ tier, these are usually displayed as Roman numerals and are for:
- First in-human dose ranging for safety determination
- Testing on participants to assess efficacy and side effects
- Testing of drug on participants to assess efficacy, effectiveness and safety
- Post marketing surveillance in public
Before in-human testing can begin, laboratory or animal testing would be required. This is called pre-clinical evaluation. So TASK provides an essential step in progressing novelties forward, ultimately leading to better healthcare treatments being made available.
For enquires, please complete the form below.